Fig. 2.

IMPA2 downregulation correlates with a poor prognosis in ccRCC patients. (a and b) Boxplot for the mRNA levels of IMPA2 in the low-risk (green box) and high-risk (red box) groups (a) that were stratified in SurvExpress Kaplan-Meier analysis (b) by the median of the transcriptional profiles in tumors from 415 ccRCC patients from the TCGA database. The band inside the box is the second quartile (the median). The upper and lower lines of box are the third and first quartiles, respectively. Box plots have lines extending vertically from the whiskers indicating minimum and maximum of all of the data. The individual points indicate outliers. In a, significant differences were analyzed by t-test. (c) The IHC results for the IMPA2 protein intensities ranged from 0 to 3. (d) Kaplan-Meier analysis for low (scores 0 and 1) and high (scores 2 and 3) IMPA2 protein levels from the IHC experiment for tumors from 40 ccRCC patients. (E and F) Cox regression test using univariable (e) and multivariable (f) modes for IMPA2 mRNA levels (high vs. low) and other pathological variables including age (median = 60 years, elder vs. younger), gender (male vs. female), pathologic T (pT, T1/T2 vs. T3/T4), pN (N1 vs. N0), pM (M1 vs. M0), stage (III/IV vs. I/II) and grade (III/IV vs. I/II) under the condition of overall survival probability for 415 ccRCC patients from the TCGA database using the SurvExpress program. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)